Potent and selective JAK2 inhibitor (IC50 < 3 nM). Exhibits >50-fold selectivity for JAK2 over JAK3. Exhibits antitumor effects and inhibits formation of lung metastases in a mouse renal cancer model. Also inhibits STAT3 signaling, tumor angiogenesis and myeloid cell migration in vivo.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 348.77. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.87 mL||14.34 mL||28.67 mL|
|5 mM||0.57 mL||2.87 mL||5.73 mL|
|10 mM||0.29 mL||1.43 mL||2.87 mL|
|50 mM||0.06 mL||0.29 mL||0.57 mL|
References are publications that support the products' biological activity.
Ioannidis S et al (2011) Discovery of 5-chloro-N2-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (AZD1480) as a novel inhibitor of the Jak/Stat pathway. J.Med.Chem. 54 262 PMID: 21138246
Xin et al (2011) Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480. Cancer Res. 71 6601 PMID: 21920898
If you know of a relevant reference for AZD 1480, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: AZD 1480, supplier, AZD1480, JAK2, inhibitors, cancer, anticancers, metastasis, angiogenesis, STAT3, signaling, potent, selective, inhibits, JAK, Kinase, Antiangiogenics, JAK, Kinase, Tocris Bioscience
Citations for AZD 1480
Citations are publications that use Tocris products.
Currently there are no citations for AZD 1480. Do you know of a great paper that uses AZD 1480 from Tocris? If so please let us know.
AZD 1480 Reviews
Average Rating:(Based on 0 Reviews)